These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 29741506)

  • 1. Recent advances in the cellular and molecular understanding of myelodysplastic syndromes: implications for new therapeutic approaches.
    Brunner AM; Steensma DP
    Clin Adv Hematol Oncol; 2018 Jan; 16(1):56-66. PubMed ID: 29741506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and emerging strategies for management of myelodysplastic syndromes.
    Saygin C; Carraway HE
    Blood Rev; 2021 Jul; 48():100791. PubMed ID: 33423844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Navigating Myelodysplastic and Myelodysplastic/Myeloproliferative Overlap Syndromes.
    Hasserjian RP; Buckstein R; Patnaik MM
    Am Soc Clin Oncol Educ Book; 2021 Mar; 41():328-350. PubMed ID: 34010050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myelodysplastic Syndromes: Diagnosis and Treatment.
    Steensma DP
    Mayo Clin Proc; 2015 Jul; 90(7):969-83. PubMed ID: 26141335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging biological therapies for the treatment of myelodysplastic syndromes.
    Zeidan AM; Stahl M; Komrokji R
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):283-300. PubMed ID: 27486848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities.
    Abou Zahr A; Bernabe Ramirez C; Wozney J; Prebet T; Zeidan AM
    Expert Rev Hematol; 2016; 9(4):377-88. PubMed ID: 26734762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.
    Stahl M; Zeidan AM
    Expert Rev Hematol; 2017 Apr; 10(4):345-364. PubMed ID: 28277851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The emerging role of immune checkpoint based approaches in AML and MDS.
    Boddu P; Kantarjian H; Garcia-Manero G; Allison J; Sharma P; Daver N
    Leuk Lymphoma; 2018 Apr; 59(4):790-802. PubMed ID: 28679300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Recent advances in the treatment of myelodysplastic syndromes].
    Gelsi-Boyer V; Vey N
    Rev Med Interne; 2006 Aug; 27(8):600-9. PubMed ID: 16713027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1
    Bewersdorf JP; Xie Z; Bejar R; Borate U; Boultwood J; Brunner AM; Buckstein R; Carraway HE; Churpek JE; Daver NG; Porta MGD; DeZern AE; Fenaux P; Figueroa ME; Gore SD; Griffiths EA; Halene S; Hasserjian RP; Hourigan CS; Kim TK; Komrokji R; Kuchroo VK; List AF; Loghavi S; Majeti R; Odenike O; Patnaik MM; Platzbecker U; Roboz GJ; Sallman DA; Santini V; Sanz G; Sekeres MA; Stahl M; Starczynowski DT; Steensma DP; Taylor J; Abdel-Wahab O; Xu ML; Savona MR; Wei AH; Zeidan AM
    Blood Rev; 2023 Jul; 60():101072. PubMed ID: 36934059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent developments in myelodysplastic syndromes.
    Bejar R; Steensma DP
    Blood; 2014 Oct; 124(18):2793-803. PubMed ID: 25237199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insight into the molecular pathophysiology of myelodysplastic syndromes: targets for novel therapy.
    Zahid MF; Patnaik MM; Gangat N; Hashmi SK; Rizzieri DA
    Eur J Haematol; 2016 Oct; 97(4):313-20. PubMed ID: 27147278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myelodysplastic syndromes: a practical approach to diagnosis and treatment.
    Barzi A; Sekeres MA
    Cleve Clin J Med; 2010 Jan; 77(1):37-44. PubMed ID: 20048028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
    Garcia-Manero G
    Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The wider perspective: twenty years of clinical trials in myelodysplastic syndromes.
    Duetz C; Cucchi DGJ; Polak TB; Janssen JJWM; Ossenkoppele GJ; Estey EH; van de Loosdrecht AA
    Br J Haematol; 2022 Jan; 196(2):329-335. PubMed ID: 34632583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New approaches to the treatment of myelodysplasia.
    List AF
    Oncologist; 2002; 7 Suppl 1():39-49. PubMed ID: 11961208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging treatment options for patients with high-risk myelodysplastic syndrome.
    Bewersdorf JP; Carraway H; Prebet T
    Ther Adv Hematol; 2020; 11():2040620720955006. PubMed ID: 33240476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it.
    Zeidan AM; Shallis RM; Wang R; Davidoff A; Ma X
    Blood Rev; 2019 Mar; 34():1-15. PubMed ID: 30314642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. More is better: combination therapies for myelodysplastic syndromes.
    Ornstein MC; Mukherjee S; Sekeres MA
    Best Pract Res Clin Haematol; 2015 Mar; 28(1):22-31. PubMed ID: 25659727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel agents for the management of myelodysplastic syndromes.
    Meletis J; Viniou N; Terpos E
    Med Sci Monit; 2006 Sep; 12(9):RA194-206. PubMed ID: 16940944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.